摘要
目的评价厄洛替尼治疗非小细胞肺癌的效果和安全性。方法采用Cochrane系统评价方法，检索Cochrane图书馆、MEDLINE、VIP、CNKI、CBM disc等电子资料库。由2名评价者共同评价纳入研究质量，对同质研究进行Meta分析。结果共纳入6个随机对照研究、3184例非小细胞肺癌患者。纳入的6个研究均表明采用了随机的方法，1个研究实施了切实有效的盲法，所有研究未提及分配隐藏，所有纳入研究均进行ITT意向性分析；Meta分析显示厄洛替尼联合化疗的反应率[OR1．10，95％CI（0．91～1．34）]、1年生存率[OR 1．04，95％CI（0．88～1．24）]均无统计学意义，厄洛替尼单药口服显示出生存优势，中位无进展生存期、中位生存期分别为2．2个月和6．7个月（P〈0．001）。结论现有研究结果显示厄洛替尼是一种有效安全的靶向抗肿瘤药物，但由于纳入研究存在选择性偏倚和测量性偏倚的可能性，势必影响结果的强度。
Objective To evaluate the efficacy and safety of erlotinib in the treatment of non-small cell lung cancer Methods The Cochrane Library, MEDLIN E, VIP, CNKI and CBM disc were searched. The quality of included studies was evaluated and meta-analysis was performed for the Resutls of homogeneous studies. Resutls Six studies involving 3184 participants with non-small cell lung cancer were included. All included studies report randomization, one report blinding, but were inadquate in reporting concealment of allocation. Meta analysis based on included studies showed that response rate of erlotinib combined with chemotherapy is not better than control group[ OR 1.10,95% CI（0. 91 - 1.34） ] ,1-year survival rate also has no statistical difference[ OR 1.04,95% CI（ 0. 88 - 1.24 ） ]. Median Progression-free survival and Median survival time of erlotinib are 2. 2 months and 6. 7months （ P 〈 0. 001 ）. Conclusions Erlotinib is an effective and safe target anti-cancer drug. Due to risk of selection bias and detection bias of included studies,the evidence is not strong enough.
出处
《实用医院临床杂志》
2009年第5期36-39,共4页
Practical Journal of Clinical Medicine
关键词
厄洛替尼
非小细胞肺癌
治疗
系统评价
Erlotinib
Non-small cell lung cancer
Treatment
Systematic review
